Recently, the FDA approved the first COVID-19 oral antiviral agents. Pfizer’s Paxlovid® (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) and Merck’s molnupiravir have been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) in the treatment of mild-to-moderate COVID-19 for people at high risk for progression to severe COVID-19.…

On January 4, 2022, the CDC updated recommendations regarding the interval between a primary series of the Pfizer/BioNTech COVID-19 vaccine and a booster dose. …

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.…

Given what we currently know about COVID-19 and the Omicron variant, CDC is shortening the recommended time for isolation from 10 days for people with COVID-19 to 5 days, if asymptomatic, followed by 5 days of wearing a mask when around others.…

Early detection means finding and diagnosing a disease earlier than if you had waited for symptoms to appear. Women whose breast cancer is detected early have…